Roche wins FDA approval for Enspryng in thyroid eye disease
The FDA approved Enspryng for adults with thyroid eye disease, the first at-home subcutaneous option, Roche said. Approval followed Phase 3 SatraGO data.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Roche said the US Food and Drug Administration approved Enspryng (satralizumab) for adults with thyroid eye disease. The company describes it as the first and only option for this condition that can be given at home by subcutaneous injection.
The approval came after priority review and rested on Phase 3 data from the SatraGO program. For Roche, it is a second US indication for a drug already authorized in 2020 for neuromyelitis optica spectrum disorder.
The company also noted that a regulatory decision on the MOGAD application is expected in January 2027.
why it matters
The new indication could expand revenue from Enspryng, though the scale will depend on uptake, pricing and payer coverage. Investors will watch whether the convenience of home dosing shifts prescribing away from infusion therapies.
tags
instruments
sources
- Roche (RHO) Wins FDA OK for Enspryng in Thyroid Eye Disease — globenewswire.com, 16 October 2026 at 05:00 UTC
- Roche Gets FDA Approval for Enspryng to Treat Thyroid Eye Disease, 16 October 2026 at 05:12 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗